B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses
| Autor: | Luisa L. Villa, Maria Beatriz Sartor de Faria Rosa, Edmund Chada Baracat, Luciana Benevides, Paulo Francisco Ramos Margarido, Kaori Yokochi, Renata Ariza Marques Rossetti, Noely Paula Cristina Lorenzi, Jesus Paula Carvalho, Ana Paula Lepique |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
B Cells medicine.medical_treatment T-Lymphocytes Cancer Treatment Uterine Cervical Neoplasms lcsh:Medicine Lymphocyte Activation Cervical Cancer Mice White Blood Cells Spectrum Analysis Techniques Animal Cells Medicine and Health Sciences Medicine Cytotoxic T cell lcsh:Science education.field_of_study B-Lymphocytes Immunity Cellular Multidisciplinary T Cells Flow Cytometry MONÓCITOS medicine.anatomical_structure Oncology Spectrophotometry B7-1 Antigen Female Immunotherapy Cytophotometry Cellular Types Research Article T cell Immune Cells Population CD40 Ligand Immunology Antigen-Presenting Cells Cytotoxic T cells Research and Analysis Methods 03 medical and health sciences Immune system Animals Humans CD40 Antigens education Antigen-presenting cell Antibody-Producing Cells Molecular Biology Techniques Molecular Biology CD86 Homeodomain Proteins Blood Cells business.industry lcsh:R Biology and Life Sciences Cancers and Neoplasms Dendritic Cells Cell Biology 030104 developmental biology Cancer research lcsh:Q B7-2 Antigen Interleukin-4 business Gynecological Tumors CD80 Cloning |
| Zdroj: | PLoS ONE, Vol 13, Iss 7, p e0199034 (2018) Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Immune evasion by tumors includes several different mechanisms, including the inefficiency of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may display a pro-tumoral role but can also be modulated to function as antigen presenting cells to T lymphocytes, capable of triggering anti-cancer immune responses. While dendritic cells, DCs, are the best APC population to activate naive T cells, DCs or their precursors, monocytes, are frequently modulated by tumors, displaying a tolerogenic phenotype in cancer patients. In patients with cervical cancer, we observed that monocyte derived DCs are tolerogenic, inhibiting allogeneic T cell activation compared to the same population obtained from patients with precursor lesions or cervicitis. In this work, we show that B lymphocytes from cervical cancer patients respond to treatment with sCD40L and IL-4 by increasing the CD80+CD86+ population, therefore potentially increasing their ability to activate T cells. To test if B lymphocytes could actually trigger anti-tumor T cell responses, we designed an experimental model where we harvested T and B lymphocytes, or dendritic cells, from tumor bearing donors, and after APC stimulation, transplanted them, together with T cells into RAG1-/- recipients, previously injected with tumor cells. We were able to show that anti-CD40 activated B lymphocytes could trigger secondary T cell responses, dependent on MHC-II expression. Moreover, we showed that dendritic cells were resistant to the anti-CD40 treatment and unable to stimulate anti-tumor responses. In summary, our results suggest that B lymphocytes may be used as a tool for immunotherapy against cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |